Evaluation of Chemotherapy Claims for Breast Cancer

乳腺癌化疗声明的评估

• 批准号: 6633994
• 负责人: XIANGLIN DU
• 金额: $ 4.08万
• 依托单位: UNIVERSITY OF TEXAS MED BR GALVESTON
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-03-01 至 2003-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6633994
• 关键词: Medicare /Medicaid; aging; body water dehydration; breast neoplasms; cancer registry /resource; clinical research; emesis; female; hospital utilization; human old age (65+); human subject; human therapy evaluation; hyperthermia; nausea; neoplasm /cancer chemotherapy; neoplasm /cancer epidemiology; outcomes research; women's health; Medicare /Medicaid; aging; body water dehydration; breast neoplasms; cancer registry /resource; clinical research; emesis; female; hospital utilization; human old age (65+); human subject; human therapy evaluation; hyperthermia; nausea; neoplasm /cancer chemotherapy; neoplasm /cancer epidemiology; outcomes research; women's health

DESCRIPTION (provided by applicant): Over the past several decades, numerous clinical trials have consistently demonstrated that chemotherapy is efficacious in both premenopausal and postmenopausal women with breast cancer. However, little is known about the use of chemotherapy and its effectiveness in the community because of a lack of large population-based data. While the Surveillance, Epidemiology and End Results (SEER) tumor registries provide data on radiation therapy and surgical treatment for breast cancer, they do not provide information on chemotherapy. They are not required to collect this information, and the medical records in oncologists' offices, where chemotherapy is likely to be administered, may not be routinely reviewed for data on the primary course of cancer-directed therapy. Medicare claims are a potential source of national data on chemotherapy use for breast cancer cases aged 65 and older. However, no study has examined the validity of this information. If Medicare claims provide accurate and complete data on chemotherapy, their utility for breast cancer research would be considerably enhanced, allowing for population-based analyses of the current uses of chemotherapy as well as effectiveness studies in the community. Therefore, we propose to examine the utility of information on chemotherapy from Medicare claims data for women aged 65 and older who have been diagnosed with breast cancer. Our approach is to identify women aged 65 years or older who have been diagnosed with breast cancer in the New Mexico Tumor Registry (a SEER registry), that can be linked with Medicare claims data by unique identifiers. We will contract with the registry to abstract the medical records on chemotherapy administration for eligible patients in all facilities including medical oncologists' offices where patients may have received chemotherapy. We will then compare information on the use of chemotherapy from medical chart review with information obtained from Medicare claims data. Our aims are 1) to determine whether Medicare data can identify women who received chemotherapy for breast cancer; 2) to determine whether Medicare data can differentiate among the specific regimens of chemotherapy; and 3) to determine whether the number of claims can be used to estimate the number of cycles of chemotherapy. Based on this information, we will characterize the nature and extent of error in using Medicare claims for chemotherapy effectiveness research among older women diagnosed with breast cancer. We will then use the Medicare-SEER linked data for all SEER areas to examine patterns and outcomes of chemotherapy among older women with breast cancer. Information generated from the medical chart reviews will also allow us to examine patterns of chemotherapy care independent of the Medicare claims data or independent of those parts of the claims that we find generate invalid estimates.

描述（由申请人提供）：在过去的几十年中，许多 临床试验始终证明化学疗法是有效的 绝经前和绝经后乳腺癌妇女。然而， 关于化疗及其在 社区由于缺乏大型基于人群的数据。而 监视，流行病学和最终结果（SEER）肿瘤注册表提供数据 关于乳腺癌的放射疗法和手术治疗，它们没有 提供有关化学疗法的信息。他们不需要收集这个 信息，以及肿瘤学家办公室中的病历 化学疗法很可能会进行，可能不会经常审查 有关癌症指导疗法的主要过程的数据。 Medicare主张是有关化学疗法使用的国家数据的潜在来源 65岁及以上的乳腺癌病例。但是，尚无研究检查 此信息的有效性。如果Medicare索赔提供准确而完整的 有关化学疗法的数据，它们的乳腺癌研究实用性将是 大大增强，允许基于人群的当前分析 化学疗法的使用以及社区的有效性研究。 因此，我们建议检查有关化学疗法信息的实用性 从诊断为65岁及以上的妇女的Medicare索赔数据中 与乳腺癌。 我们的方法是确定年龄在65岁以上的妇女 在新墨西哥州肿瘤注册表中被诊断出患有乳腺癌（先知 注册表），可以通过唯一标识符将其与Medicare索赔数据联系起来。 我们将与注册表签订合同，以将医疗记录抽象 所有设施中合格患者的化学疗法给药 医学肿瘤学家办公室患者可能已经接受了化学疗法。我们 然后将比较有关从医学图中使用化学疗法的信息 从Medicare索赔数据获得的信息进行审查。我们的目标是1） 确定医疗保险数据是否可以识别接受化疗的女性 用于乳腺癌； 2）确定医疗保险数据是否可以区分 在化学疗法的特定方案中； 3）确定是否 索赔数量可用于估计化学疗法的周期数量。 基于此信息，我们将表征错误的性质和程度 在使用Medicare主张进行化学疗法的有效性研究中 妇女被诊断出患有乳腺癌。然后，我们将使用链接的Medicare-seer 所有SEER领域的数据，以检查化学疗法的模式和结果 老年乳腺癌的妇女。从医疗图表产生的信息 评论还将使我们能够独立研究化学疗法护理的模式 Medicare索赔数据或独立于我们的主张的部分 查找生成无效的估计。